2 1 Shi Ji Jing Ji Bao Dao·2025-07-23 12:03Group 1 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) faced its eighth consecutive trading halt on July 23 due to significant operational challenges stemming from a contract termination with its subsidiary REGEN Biotech, Inc. [1] - REGEN Biotech announced on July 18 that it had sent a termination notice to Datuo Medical (Shanghai) Co., Ltd., which will result in the loss of exclusive distribution rights for the AestheFill product in mainland China [1] - The termination of the distribution agreement is expected to lead to a substantial decrease in revenue and profit for *ST Suwu's medical aesthetics segment in the second half of 2025 [1] Group 2 - On July 13, *ST Suwu received a notice from the China Securities Regulatory Commission (CSRC) regarding administrative penalties for inflating revenue, costs, and profits, with false records in annual reports from 2020 to 2023 [2] - The CSRC plans to impose a fine of 10 million yuan and issue warnings to related personnel, which may trigger mandatory delisting due to serious violations of the Shanghai Stock Exchange listing rules [2] - Following the CSRC's notice, *ST Suwu has been placed under a delisting risk warning by the Shanghai Stock Exchange since July 14 [2]